Journal of Digestive Cancer Reports

Korean Society of Gastrointestinal Cancer Research (대한소화기암연구학회)
권호 표지
DOI QR코드

DOI QR Code

Immune Checkpoint Inhibitors in Advanced Colorectal Cancer

진행성 직결장암에서의 면역관문억제제의 효과

  • Cheon, Jaekyung (Department of Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine)
  • 천재경 (차의과학대학교 의학전문대학원 분당차병원 혈액종양내과)
  • Received : 2021.10.21
  • Accepted : 2021.11.22
  • Published : 2021.12.01
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424. https://doi.org/10.3322/caac.21492
  2. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509-2520. https://doi.org/10.1056/NEJMoa1500596
  3. Le DT, Kim TW, Van Cutsem E, et al. Phase II open-label study of pembrolizumab in treatment-refractory, micro-satellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol 2020;38:11-19.
  4. Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 2017;18:1182-1191. https://doi.org/10.1016/S1470-2045(17)30422-9
  5. Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 2018;36:773-779. https://doi.org/10.1200/JCO.2017.76.9901
  6. Lenz HJ, Lonardi S, Zagonel V, et al. Nivolumab (NIVO)+low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): two-year clinical update. J Clin Oncol 2020;38:4040. https://doi.org/10.1200/jco.2020.38.15_suppl.4040
  7. Andre T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med 2020;383:2207-2218. https://doi.org/10.1056/NEJMoa2017699
  8. Andre T, Amonkar M, Norquist JM, et al. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. Lancet Oncol 2021;22:665-677. https://doi.org/10.1016/S1470-2045(21)00064-4